New research from VCU Massey Cancer Center — published Thursday in Cell Reports — demonstrated that a novel targeted therapy could be an effective treatment option for a deadly pediatric cancer known as neuroblastoma.
Children with high-risk neuroblastoma can now access a specialized, targeted radiation treatment called MIBG therapy at Children’s Hospital Los Angeles—one of the largest neuroblastoma programs in the country and the only pediatric facility in Southern California and the Southwestern United States to offer this treatment.
Additional therapy between two standard phases of treatment may be especially effective in patients with stable metastatic cancer.
St. Jude Children’s Research Hospital scientists have identified the primary target of the experimental cancer drug CX-5164, revealing a possible risk for late effects of treatment.
In a breakthrough for the treatment of aggressive solid cancers, researchers at Children’s Hospital of Philadelphia (CHOP) have developed a novel cancer therapy that targets proteins inside cancer cells that are essential for tumor growth and survival but have been historically impossible to reach. Using the power of large data sets and advanced computational approaches, the researchers were able to identify peptides that are presented on the surface of tumor cells and can be targeted with “peptide-centric” chimeric antigen receptors (PC-CARs), a new class of engineered T cells, stimulating an immune response that eradicates tumors.
UChicago Medicine physician-scientists aimed to find out how the immune systems of children with a type of cancer called neuroblastoma respond to tumors. The answer to this question could help guide the treatment of pediatric patients.
A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was highly effective in mice implanted with human neuroblastoma tissue.
Neuroblastoma is the deadliest and most common solid cancer in young children the world over, accounting for 15 per cent of all childhood cancer deaths. But Australian researchers are taking the first steps to find the cause and better treatments for this devastating disease which affects children under the age of five.
Un nuevo estudio de los investigadores de Mayo Clinic identificó que un gen de inestabilidad cromosómica, el USP24, está a menudo ausente en los pacientes pediátricos con neuroblastoma (tipo agresivo de cáncer cerebral en niños). El resultado ofrece una perspectiva importante sobre el desarrollo de esta enfermedad.
A new study by Mayo Clinic researchers has identified that a chromosome instability gene, USP24, is frequently missing in pediatric patients with neuroblastoma, an aggressive form of childhood cancer. The finding provides important insight into the development of this disease. The study is published in Cancer Research, the journal of the American Association for Cancer Research.
Researchers have used insight from a comprehensive genomic analysis of neuroblastoma to learn about the process driving one of the most common childhood solid tumors.
Mount Sinai researchers have identified a targeted therapy for adolescent patients with neuroblastoma, a deadly pediatric nerve cancer, who would otherwise have no treatment options, according to a study published in October in Cancer Cell.
Roswell Park’s Dr. Clare Twist led an effort to develop and validate a new treatment algorithm for infants and children with neuroblastoma. In a new study in the Journal of Clinical Oncology, the team reports that many patients can safely receive less extensive therapy.